Stock ABOS ACUMEN PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Acumen Pharmaceuticals, Inc.

Equities

ABOS

US00509G2093

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
3.17 USD -0.63% Intraday chart for Acumen Pharmaceuticals, Inc. +0.63% -17.45%
04/04 Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug MT
04/04 Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate MT

Evolution of the average Target Price on Acumen Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

2a1f5fd89d.yQGKdnMlXyVcJBLh1dy-yuTQSGYKKVn4xfzIvqAsYDc.oFjgQz9ObWIJcXamhbTTv7OGHj4_WmufkK_6541POna-T8AaJnAsZyxBXw~0c7d7ba35a3b2732b3b4dc99a05a0abe

Analyst Recommendations on Acumen Pharmaceuticals, Inc.

Deutsche Bank Initiates Coverage on Acumen Pharmaceuticals With Buy Rating, $8 Price Target MT
UBS Adjusts Acumen Pharmaceuticals Price Target to $15 From $16, Maintains Buy Rating MT
BofA Securities Reinstates Acumen Pharmaceuticals at Buy With $14 Price Target MT
In wait-and-see mode before Tesla and Netflix Our Logo
Cantor Fitzgerald Starts Acumen Pharmaceuticals at Overweight With $13 Price Target MT
Credit Suisse Lowers Acumen Pharmaceuticals' Price Target to $13 From $16, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating MT
Credit Suisse Trims Acumen Pharmaceuticals' Price Target to $16 From $17, Keeps Outperform Rating MT
BTIG Adjusts Acumen Pharmaceuticals' Price Target to $22 From $15, Reiterates Buy Rating MT
UBS Adjusts Acumen Pharmaceuticals Price Target to $16 From $27, Maintains Buy Rating MT
BTIG Starts Acumen Pharmaceuticals at Buy With $15 Price Target MT
HC Wainwright Initiates Coverage on Acumen Pharmaceuticals With Buy Rating, $15 Price Target MT
Credit Suisse Lowers Acumen Pharmaceuticals' PT to $17 from $26 on Updated Assumptions for ACU193 Pricing, FY Model Updates; Keeps Outperform Rating MT
Stifel Nicolaus Lowers Price Target for Acumen Pharmaceuticals to $17 From $27, Maintains Buy Rating MT
BofA Securities Upgrades Acumen Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $14 From $16 MT
ACUMEN PHARMACEUTICALS : Credit Suisse Starts Acumen Pharmaceuticals at Outperform with $26 PT, Notes Sole Product's High-Risk, High-Return Potential MT
ACUMEN PHARMACEUTICALS : Stifel Initiates Acumen Pharmaceuticals at Buy Rating With $27 Price Target MT
ACUMEN PHARMACEUTICALS : UBS Starts Acumen Pharmaceuticals at Buy With $27 Price Target MT
ACUMEN PHARMACEUTICALS : BofA Securities Starts Acumen Pharmaceuticals at Neutral With $20 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.17 USD
Average target price
12.8 USD
Spread / Average Target
+303.79%
High Price Target
15 USD
Spread / Highest target
+373.19%
Low Price Target
10 USD
Spread / Lowest Target
+215.46%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Acumen Pharmaceuticals, Inc.

Deutsche Bank Securities
UBS
BofA Securities
Cantor Fitzgerald
Credit Suisse
BTIG
HC Wainwright
Stifel Nicolaus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ABOS Stock
  4. Consensus Acumen Pharmaceuticals, Inc.